Results 11 to 20 of about 2,997 (148)

Glycopyrronium bromide is a new long-acting anticholinergic drug for the treatment of COPD

Медицинский совет, 2014
Glycopyrronium is a new powerful quick-acting anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease. Glycopyrronium is powder in Breezhaler® inhalation device.
S. N. Avdeev, S. Y. Chikina
doaj   +2 more sources

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit [PDF]

International Journal of COPD, 2012
Charlotte Suppli UlrikDepartment of Pulmonary Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, DenmarkBackground: Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive ...
Ulrik CS
doaj   +2 more sources

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study

International Journal of COPD, 2015
Chen Wang,1 Tieying Sun,1 Yijiang Huang,2 Michael Humphries,3 Lingyan Bai,3 Lilly Li,3 Qian Wang,3 Pearl Kho,4 Roz Firth,4 Peter D'Andrea51Beijing Hospital, Dongcheng District, Beijing, People's Republic of China; 2Hainan Provincial People's ...
Wang C, Sun T, Huang Y, Humphries M, Bai L, Li L, Wang Q, Kho P, Firth R, D’Andrea P   +9 more
doaj   +1 more source

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD

ERJ Open Research, 2016
This study compared the efficacy and safety of once-daily umeclidinium 62.5 µg with once-daily glycopyrronium 50 µg in patients with moderate-to-severe chronic obstructive pulmonary disease.
Tara Rheault, Sanjeev Khindri, Mitra Vahdati-Bolouri, Alison Church, William A. Fahy   +4 more
doaj   +2 more sources

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data

International Journal of COPD, 2015
Anthony D D’Urzo,1 Edward M Kerwin,2 Kenneth R Chapman,3 Marc Decramer,4 Robert DiGiovanni,5 Peter D’Andrea,6 Huilin Hu,6 Pankaj Goyal,5 Pablo Altman6 1Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada ...
D’Urzo AD, Kerwin EM, Chapman KR, Decramer M, DiGiovanni R, D’Andrea P, Hu H, Goyal P, Altman P   +8 more
doaj   +1 more source

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD

International Journal of COPD, 2015
Anoop Prakash,1 K Suresh Babu,2 Jaymin B Morjaria1,31Department of Respiratory Medicine, Castle Hill Hospital, Cottingham, 2Department of Respiratory Medicine, Queen Alexandra Hospital, Cosham, Portsmouth, 3Department of Academic Respiratory Medicine ...
Prakash A, Babu KS, Morjaria JB
doaj   +1 more source

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]

International Journal of COPD, 2014
Buhl R, Banerji D. Int J Chron Obstruct Pulmon Dis. 2012;7:729–741. On page 737 in the first paragraph of the "Safety" section, the final sentence "Serious adverse events occurred with a slightly lower frequency in the glycopyrronium
Buhl R, Banerji D
doaj   +1 more source

Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis

International Journal of COPD, 2013
Andreas Karabis,1 Leandro Lindner,2 Michelle Mocarski,3 Eline Huisman,1 Andrew Greening4 1MAPI Consultancy, AX Houten, The Netherlands; 2Almirall SA, Barcelona, Spain; 3Health Economics and Outcomes Research, Forest Research Institute, Jersey City, NJ ...
Karabis A, Lindner L, Mocarski M, Huisman E, Greening A   +4 more
doaj   +1 more source

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)

International Journal of COPD, 2016
Jose M Marin,1 Kai M Beeh,2 Andreas Clemens,3 Walter Castellani,4 Lennart Schaper,5 Dinesh Saralaya,6 Anthony Gunstone,7 Ricard Casamor,8 Konstantinos Kostikas,3 Maryam Aalamian-Mattheis3 1University Hospital Miguel Servet, IISAragón, CIBERES ...
Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M   +9 more
doaj   +1 more source

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD [PDF]

, 2016
BACKGROUND: Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who ...
Wedzicha JA, Bálint Beatrix, Patalano F, Ayers RT, Banerji D, Fogel R, Kollaborációs szervezet: FLAME Investigators, Vestbo J, Vogelmeier CF, Chapman KR, Somfay Attila, Roche N, Thach C, et al.   +13 more
core   +5 more sources